PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest
Sign Up to like & getrecommendations! Published in 2019 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-019-04601-3
Abstract: Peptide receptor radionuclide therapy (PRRT) is effective for metastatic/inoperable neuroendocrine tumors (NETs). Imaging response assessment is usually efficient subsequent to treatment completion. Blood biomarkers such as PRRT Predictive Quotient (PPQ) and NETest are effective in… read more here.
Keywords: response; ppq; recist; non responders ... See more keywords
177Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study
Sign Up to like & getrecommendations! Published in 2020 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-020-04873-0
Abstract: Purpose In March 2014, we reported the activity and safety of 177 Lu-DOTA-octreotate peptide receptor radionuclide therapy (Lu-PRRT) at two different dosages (18.5 GBq and 27.5 GBq in 5 cycles) in patients with progressive metastatic gastrointestinal neuroendocrine tumors… read more here.
Keywords: phase; year follow; gastrointestinal neuroendocrine; prrt ... See more keywords
Strategies Towards Improving Clinical Outcomes of Peptide Receptor Radionuclide Therapy
Sign Up to like & getrecommendations! Published in 2021 at "Current Oncology Reports"
DOI: 10.1007/s11912-021-01037-7
Abstract: Peptide receptor radionuclide therapy (PRRT) with [177Lu-DOTA0,Tyr3] octreotate is an effective and safe second- or third-line treatment option for patients with low-grade advanced gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN). In this review, we will focus on… read more here.
Keywords: radionuclide therapy; prrt; receptor radionuclide; receptor ... See more keywords
Assessment of hormonal levels as prognostic markers and of their optimal cut-offs in small intestinal neuroendocrine tumours grade 2
Sign Up to like & getrecommendations! Published in 2020 at "Endocrine"
DOI: 10.1007/s12020-020-02534-8
Abstract: Small intestinal neuroendocrine tumours (siNETs) with a Ki-67 proliferation index between 3 and 20% belong to WHO grade 2. Response to treatment may be monitored by blood chromogranin A (CgA) and urine 5-hydroxyindoleacetic acid (5HIAA).… read more here.
Keywords: small intestinal; treatment; prrt; neuroendocrine tumours ... See more keywords
Resistant functioning and/or progressive symptomatic metastatic gastroenteropancreatic neuroendocrine tumors: efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy in this setting
Sign Up to like & getrecommendations! Published in 2018 at "Nuclear Medicine Communications"
DOI: 10.1097/mnm.0000000000000926
Abstract: Background and aims Functioning and symptomatic disease resistant to conventional therapies constitutes a subset amongst neuroendocrine tumors (NETs) that are commonly considered for peptide receptor radionuclide therapy (PRRT). The aim of this study was to… read more here.
Keywords: progressive symptomatic; prrt; neuroendocrine tumors; receptor radionuclide ... See more keywords
177Lu-DOTATATE Theranostics
Sign Up to like & getrecommendations! Published in 2023 at "Clinical Nuclear Medicine"
DOI: 10.1097/rlu.0000000000004599
Abstract: Purpose Pretreatment predictions of absorbed doses can be especially valuable for patient selection and dosimetry-guided individualization of radiopharmaceutical therapy. Our goal was to build regression models using pretherapy 68Ga-DOTATATE PET uptake data and other baseline… read more here.
Keywords: pet uptake; 177lu dotatate; dotatate; pretherapy 68ga ... See more keywords
Revolutionizing Thyroid Cancer Treatment: Restoring Radioiodine Avidity After PRRT-A Case Series.
Sign Up to like & getrecommendations! Published in 2025 at "Clinical nuclear medicine"
DOI: 10.1097/rlu.0000000000005809
Abstract: Four cases of thyroid cancer became radioiodine-refractory following conventional treatments. While no RAI-avid lesion was noticed in the initial whole-body radioiodine scan (WBIS), their metastatic foci had trace avidity. They were diagnosed as TENNIS; 2… read more here.
Keywords: revolutionizing thyroid; prrt; thyroid cancer; avidity ... See more keywords
False-positive [68Ga]Ga-FAPI-04 PET/CT Following Treatment of 177Lu-DOTATATE PRRT in a Patient With Metastatic High-grade Well-differentiated Neuroendocrine Tumor.
Sign Up to like & getrecommendations! Published in 2025 at "Clinical nuclear medicine"
DOI: 10.1097/rlu.0000000000006181
Abstract: We present a high-grade well-differentiated NET with large lesions that demonstrated both SSTR and [18F]F-FDG avidity on baseline PET/CT, an outstanding response following 177Lu-DOTATATE-PRRT with complete resolution of SSTR and [18F]F-FDG uptake, and significant size… read more here.
Keywords: well differentiated; high grade; prrt; 68ga fapi ... See more keywords
Role of neoadjuvant peptide receptor radionuclide therapy in unresectable and metastatic gastro‐entero‐pancreatic neuroendocrine neoplasms: A scoping review
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Neuroendocrinology"
DOI: 10.1111/jne.13425
Abstract: Peptide receptor radionuclide therapy (PRRT) is an established therapy for metastatic neuroendocrine neoplasms (NEN). The role of PRRT as a neoadjuvant treatment prior to surgery or other local therapies is uncertain. This scoping review aimed… read more here.
Keywords: therapy; role; radionuclide therapy; receptor radionuclide ... See more keywords
PRRT in high‐grade digestive neuroendocrine neoplasms (NET G3 and NEC)
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Neuroendocrinology"
DOI: 10.1111/jne.13443
Abstract: Peptide receptor radionuclide therapy (PRRT) has been primarily studied in low and intermediate‐grade digestive neuroendocrine tumors (NET G1‐G2). The documentation of a similar benefit for high‐grade digestive neuroendocrine neoplasms (NEN) has been limited. This review… read more here.
Keywords: high grade; grade digestive; grade; prrt ... See more keywords
Expanding the Indication for Novel Theranostic 177Lu-Dotatate Peptide Receptor Radionuclide Therapy: Proof-of-Concept of PRRT in Merkel Cell Cancer
Sign Up to like & getrecommendations! Published in 2019 at "Case Reports in Oncology"
DOI: 10.1159/000496335
Abstract: The field of theranostics is a new nuclear medicine tool being utilized in the treatment of different types of cancers. It couples receptor-specific based imaging predicting and guiding response to receptor-specific based radionuclide therapies. For… read more here.
Keywords: therapy; 177lu dotatate; dotatate; prrt ... See more keywords